Skip to main content
Premium Trial:

Request an Annual Quote

InformedDNA, NIA Magellan Collaborate on Genetics Benefits

NEW YORK (GenomeWeb) – InformedDNA announced on Monday a collaboration with NIA Magellan to offer an evidence-based genetics benefits program.

As the number of commercially available genetic tests and the inappropriate use of such tests grow rapidly, the collaboration "provides a critical solution by offering genetic testing guidance by independent genetics specialists to patients and physicians alike," St. Petersburg, Fla.-based InformedDNA said in a statement.

The company has a national network of board-certified genetics specialists to provide clinical review services, ensuring appropriate use of genetics tests and delivering cost savings, it said. It will couple its services with NIA Magellan's solutions to deliver cost-effective and clinically actionable genetic testing, it added.

NIA Magellan is a division of healthcare management firm Magellan Health.

"[D]eploying InformedDNA's genetics expertise within NIA Magellan's established technology infrastructure allows InformedDNA to continue our rapid growth with health plan customers of all sizes," InformedDNA CEO David Nixon said.  

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.